{"nctId":"NCT01361594","briefTitle":"Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery","startDateStruct":{"date":"2011-06"},"conditions":["Diabetes"],"count":338,"armGroups":[{"label":"Intensive insulin treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Regular insulin (intensive treatment)"]},{"label":"Conventional insulin treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Regular Insulin (conventional treatment)"]}],"interventions":[{"name":"Regular insulin (intensive treatment)","otherNames":[]},{"name":"Regular Insulin (conventional treatment)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males or females between the ages of 18 and 80 years undergoing CABG +/- valve surgery.\n2. Post surgical hyperglycemia (BG \\> 140 mg/dl).\n3. Patients with and without a history of type 2 diabetes\n\nExclusion Criteria:\n\n1. Patients requiring combination CABG with additional procedures such aorta replacement.\n2. Patients with severely impaired renal function (serum creatinine â‰¥3.0 mg/dl or GFR \\< 30 ml/min) or clinically significant hepatic failure.\n3. Subjects with acute hyperglycemic crises such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state.\n4. Moribund patients and those at imminent risk of death (brain death or cardiac standstill).\n5. Patients or next-to-kin with mental condition rendering the subject or family member unable to understand the nature, scope, and possible consequences of the study.\n6. Female subjects who are pregnant or breast-feeding at time of enrollment into the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects That Were Diagnosed for Peri-operative Complications","description":"Number of participants that presented at least 1 complications including sternal wound infection, bacteremia, acute renal failure, respiratory failure, and major cardiovascular events (MACE) during the current hospitalization and up to 6 months after hospitalization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Glycemic Control","description":"1. Hyperglycemic events (BG \\> 200 mg/dL) in ICU and non-ICU\n2. Hypoglycemic events (BG \\< 70 mg/dl; severe hypoglycemia (BG \\< 40 mg/dl).","classes":[]},{"type":"SECONDARY","title":"Major Cardiovascular Events","description":"1. Acute myocardial infarction : (1) typical increase and gradual decrease (troponin) or (2) more rapid increase and decrease (creatine kinase MB) of biochemical markers of myocardial necrosis with at least one of the following: (a) ischemic symptoms, (b) development of pathologic Q waves on the electrocardiogram, (c) electrocardiographic changes indicative of ischemia (ST-segment elevation or depression), or (d) coronary artery intervention (e.g., coronary angioplasty).\n2. Congestive heart failure\n3. Cardiac arrhythmias: malignant arrhythmia","classes":[]},{"type":"SECONDARY","title":"Acute Renal Failure","description":"new-onset abnormal renal function: serum creatinine \\> 2.0 mg/dL or an increment level \\> 50% from baseline","classes":[]},{"type":"SECONDARY","title":"Respiratory Failure, Defined as PaO2 Value < 60 mm Hg While Breathing Air or a PaCO2 > 50 mm Hg.","description":"Respiratory failure, defined as PaO2 value \\< 60 mm Hg while breathing air or a PaCO2 \\> 50 mm Hg.","classes":[]},{"type":"SECONDARY","title":"ICU and Hospital Length of Stay, and ICU Readmissions","description":"ICU and hospital length of stay, and ICU readmissions","classes":[]},{"type":"SECONDARY","title":"Surgical Wound Infection","description":"superficial and deep sternal wound infection","classes":[]},{"type":"SECONDARY","title":"Pneumonia (CDC Criteria)","description":"Pneumonia (CDC criteria)","classes":[]},{"type":"SECONDARY","title":"Cerebrovascular Events","description":"permanent stroke and reversible ischemic neurologic deficit.","classes":[]},{"type":"PRIMARY","title":"Hospital Mortality","description":"Mortality is defined as death occurring during admission, either during ICU or after transition to non-ICU admission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Ventilatory Support and ICU Readmission","description":"Duration of ventilatory support and ICU readmission","classes":[]},{"type":"SECONDARY","title":"Thirty Day Mortality","description":"Thirty day mortality","classes":[]},{"type":"SECONDARY","title":"Number of Hospital Readmissions and Emergency Room Visits","description":"Number of hospital readmissions and emergency room visits","classes":[]},{"type":"SECONDARY","title":"Incidence of Organ Failures Assessed by the Daily SOFA Score","description":"Incidence of organ failures assessed by the daily SOFA score","classes":[]},{"type":"SECONDARY","title":"Measures of Inflammation","description":"Measures of inflammation (C-reactive protein, TNF-alpha; IL-6) and oxidative stress markers","classes":[]},{"type":"SECONDARY","title":"Major Cardiovascular Events","description":"1. Acute myocardial infarction : (1) typical increase and gradual decrease (troponin) or (2) more rapid increase and decrease (creatine kinase MB) of biochemical markers of myocardial necrosis with at least one of the following: (a) ischemic symptoms, (b) development of pathologic Q waves on the electrocardiogram, (c) electrocardiographic changes indicative of ischemia (ST-segment elevation or depression), or (d) coronary artery intervention (e.g., coronary angioplasty).\n2. Congestive heart failure\n3. Cardiac arrhythmias: malignant arrhythmia","classes":[]},{"type":"SECONDARY","title":"Surgical Wound Infection","description":"Superficial and deep sternal wound infection","classes":[]},{"type":"SECONDARY","title":"Pneumonia (CDC Criteria)","description":"Pneumonia (CDC criteria)","classes":[]},{"type":"SECONDARY","title":"Cerebrovascular Events","description":"permanent stroke and reversible ischemic neurologic deficit","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":63,"n":151},"commonTop":["Hypoglycemia (immediately after treatment)","Surgical re-intervention","ICU Re-admission","Hypoglycemia (ICU)"]}}}